CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
21mg transdermal nicotine patch (Nicoderm CQ) +2 moredrug
Likely dose
21mg transdermal nicotine patch (Nicoderm CQ)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00699556
NCT00699556Phase 2Completed
CompareCT.gov

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

Yale University·interventional·Posted Jun 18, 2008·Updated Mar 12, 2018

In Brief

A Phase 2 clinical trial evaluating 21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, and 1 other intervention for Alcohol Drinking. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Drinking
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 18, 2008
Enrollment StartJan 1, 2006
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 18.0 years ago

Interventions

21mg transdermal nicotine patch (Nicoderm CQ)drug

21mg transdermal nicotine patch

1mg nicotine nasal spraydrug

two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.

placebo nasal spraydrug

saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.